Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
“It sounds almost too good to be true: a cheap and simple drug that kills almost all cancers by switching off their “immortality”. The drug, dichloroacetate (DCA), has already been used for years to treat rare metabolic disorders and so is known to be relatively safe.
The challenge, as always, is to find research about DCA and multiple myeloma. And I simply, have never found information about DCA and MM.
At most, according to the research below, DCA is an integrative therapy for myeloma and the chemotherapy regimen called bortezomib aka velcade.
Wait…did I read that right?! A multiple myeloma therapy that is “cheap, safe and “kill most cancers”.”
On the one hand, I believe that there is no such thing as a magic bullet cancer therapy. One therapy will never be able to get rid of all cancers at all stages in all people.
However, I do think that there are therapies that are:
The challenge is to find “evidence-based” research. Again, not the kind of research that conventional oncology may require to approve a therapy for the standard-of-care but enough evidence to elevate the therapy above hearsay and anecdotal testimonials.
Most importantly, the second study linked and excerpted below indicates that DCA is the ideal integrative myeloma therapy- that is, DCA is cytotoxic to MM by itself and it enhances the efficacy of a standard-of-care MM chemotherapy regimen called bortezomib aka Velcade.
For more information about DCA in addition to other evidence-based, conventional and non-conventional myeloma therapies, scroll down the page, post a question or comment and I will reply ASAP.
“Dichloroacetic acid, often abbreviated DCA, is the chemical compound with formula CHCl
2COOH. It is an acid, an analogue of acetic acid, in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms. The salts and esters of dichloroacetic acid are called dichloroacetates. Salts of DCA have been studied as potential drugs because they inhibit the enzyme pyruvate dehydrogenase kinase.
Although preliminary studies have shown DCA can slow the growth of certain tumors in animal studies and in vitro studies, “Available evidence does not support the use of DCA for cancer treatment at this time.”“
“Myeloma cells display aerobic glycolysis and DCA may complement clinically used MM therapies to inhibit disease progression…
Dichloroacetate induced apoptosis and inhibited the proliferation of MM cell lines- As DCA-mediated increases in superoxide production can lead to apoptosis (Cao et al, 2008; Michelakis et al, 2008)..
Dichloroacetate increased the sensitivity of MM cell lines to the chemotherapeutic drug bortezomib-However, DCA administered in combination with bortezomib significantly prolonged (**P<0.01) the survival of myeloma-bearing mice compared with control mice (overall survival: DCA+bortezomib-treated mice 28.5 days vs control mice 22 days; Figure 5A). After 18 days of treatment, neither DCA alone or DCA+bortezomib treatment affected serum lambda concentration compared with that in control mice (Figure 5B). However, bortezomib administered alone significantly reduced (*P<0.05) serum lambda concentration compared with that of control mice (Figure 5B).
Over the past year or two there have been several articles in the news and on the internet about DCA, which was claimed to be cheap, safe and “kill most cancers”.
Understandably this caused a great deal of interest, especially as DCA is an off-patent drug and appears to be non-toxic to humans (although it can cause significant side effects, as we’ll see later).”
Targeting of tumor metabolism is emerging as a novel therapeutic strategy against cancer. Dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenase kinase (PDK), has been shown to exert a potent tumoricidal action against a variety of tumor cells…
The findings of this study shed a new light with respect to some of the novel mechanisms underlying the antitumor action of DCA and thus may have immense clinical applications.”